About: Impact of COVID‐19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of COVID‐19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Impact of COVID‐19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China
Creator	He, Yao Chen, Yan Chen, Min-Hu Ghosh, Subrata Mao, Ren Zhu, Liang-Ru Qiu, Yun Shen, Bo Iacucci, Marietta He, Jin-Shen Tan, Jin-Yu Ben-Horin, Shomron Chen, Bai-Li Li, Xiao-Zhi Liu, Zhan-Ju Zeng, Zhi-Rong Zhang, Ying-Fan
source	Medline; PMC
abstract	BACKGROUND AND AIMS: Epidemics pose a great challenge to health care of patients. However, the impact of unprecedented situation of COVID‐19 outbreak on health care of inflammatory bowel disease (IBD) patients in real‐world setting has seldom been investigated. METHODS: We performed an observational study in a tertiary referral IBD center in China. The mode of health care and medication use was compared before and after COVID‐19 outbreak. Electronic questionnaire surveys were performed among gastroenterologists and IBD patients to investigate the impact of COVID‐19 outbreak on their attitudes towards telemedicine. RESULTS: COVID‐19 outbreak resulted in substantial decrease of patients participating in standard face‐to‐face visit during 1 month post‐outbreak (n = 51) than pre‐outbreak (n = 249), whereas the participation in telemedicine was significantly higher than comparable period in 2019 (414 vs 93). During the 1 month after COVID‐19 outbreak, 39 (39/56, 69.6%) patients had their infliximab infusion postponed with the mean delay of 3 weeks. The immunomodulator use was similar between pre‐outbreak and post‐outbreak. Six elective surgeries were postponed for a median of 43 days. In post‐outbreak period, 193 (193/297, 64.98%) of the surveyed physicians have used telemedicine with an increase of 18.9% compared with 46.13% (137/292) in the pre‐outbreak period (P < 0.001); 331 (331/505, 65.54%) of the surveyed IBD patients supported that the use of telemedicine should be increased in future health care. CONCLUSION: COVID‐19 outbreak resulted in a great change in health‐care access among IBD patients including decrease in standard face‐to‐face visit and delay of biologics use. There was an increased use and need of telemedicine after COVID‐19 outbreak.
has issue date	2020-08-16(xsd:dateTime)
bibo:doi	10.1111/jgh.15205
bibo:pmid	32738060
has license	no-cc
sha1sum (hex)	783df505c0d673a773037f700f580aaddc61bf5d
schema:url	https://doi.org/10.1111/jgh.15205
resource representing a document's title	Impact of COVID‐19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South China
has PubMed Central identifier	PMC7436411
has PubMed identifier	32738060
schema:publication	J Gastroenterol Hepatol
resource representing a document's body	covid:783df505c0d673a773037f700f580aaddc61bf5d#body_text
is schema:about of	named entity 'Impact' named entity 'IBD' named entity 'IBD' named entity 'telemedicine' named entity 'IBD' named entity 'WeChat' named entity 'telemedicine' named entity 'trough level' named entity 'immunogenicity' named entity 'IBD' named entity 'telemedicine' named entity 'South China' named entity 'steroids' named entity 'COVID-19 outbreak' named entity 'telemedicine' named entity 'IBD' named entity 'COVID-19' named entity 'immunomodulators' named entity 'methotrexate' named entity 'IBD' named entity 'telemedicine' named entity 'vedolizumab' named entity 'COVID' named entity 'Inflammatory Bowel Diseases' named entity 'biologics' named entity 'fecal calprotectin' named entity 'health care' named entity 'COVID-19 outbreak' named entity 'Crohn's disease' named entity 'IBD' named entity 'tumor necrosis factor' named entity 'perfect solution' named entity 'telemedicine' named entity 'Statistical analysis' named entity 'IBD' named entity 'drug delivery' named entity 'outpatient clinic' named entity 'telemedicine' named entity 'drug prescriptions' named entity 'IBD' named entity 'C-reactive protein' named entity 'respiratory symptoms' named entity 'Chinese Lunar New Year' named entity 'inflammatory bowel disease' named entity 'fever' named entity 'COVID-19' named entity 'trough level' named entity 'health care' named entity 'IBD' named entity 'IBD' named entity 'inflammatory bowel disease' named entity 'higher risk' named entity 'IBD' named entity 'respiratory symptoms' named entity 'IBD' named entity 'telemedicine' named entity 'Chinese people' named entity 'fecal calprotectin' named entity 'methotrexate' named entity 'COVID' named entity 'telemedicine' named entity 'health care' named entity 'corticosteroid' named entity 'IBD' named entity 'cough'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software